AB SCIENCE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.96 EUR | +1.24% |
|
-1.90% | -44.87% |
| 04/04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
| 03/04 | AB Science: reconsideration possible for masitinib in ALS | CF |
ETFs positioned on AB Science
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q4 2023 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.936
EUR
Average target price
6.895
EUR
Spread / Average Target
+256.15%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.87% | 106M | |
| +3.89% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +21.35% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- AB Stock
- Funds and ETFs AB Science
